ARVN ▼ -4.0% - Arvinas, Inc.
$ARVN - Arvinas to Present Novel Biomarker Data from the Phase 1 Clinical Trial for ARV-102, a PROTAC LRRK2 Degrader, at the 2026 International Congress of Parkinson’s Disease and Movement Disorders®
01-OCT-2026 04:01 PM ET
Share this post
More filings for $ARVN
ARVN ▼ -0.1% - Arvinas, Inc.Sep 29, 2026ARVN ▲ +0.8% - Arvinas, Inc.Sep 28, 2026ARVN ▼ -2.7% - Arvinas, Inc.Sep 3, 2026ARVN ▲ +0.7% - Arvinas, Inc.Sep 1, 2026ARVN - Arvinas, Inc. - SEC Filing Update (14-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 15, 2026
View full $ARVN filing history →💬 Comments
Loading comments…
Leave a comment